LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Company Announcement no. 12/2008

To: OMX Nordic Exchange			Hørsholm, Denmark, March 31, 2008


 LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a) 

Hørsholm, Denmark, March 31, 2008; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and persons /
companies closely associated with these. 

Name	                  Claus Braestrup
Reason for reporting	Chairman of the Board of Directors
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060048148
Type of transaction	Purchase of shares
Date of transaction	March 28, 2008
Relevant market	         OMX Nordic Exchange
Number of traded securities	3,000
Market value	         DKK 72,000


About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). 

For further information, please visit www.lcpharma.com.

 
Contact:
LifeCycle Pharma A/S
Hans Christian Teisen, +45 2030 6985
SVP and CFO
HCT@lcpharma.com